In addition to the favorable market conditions, the Middle East also offers a supportive regulatory environment for biopharma companies. Regulatory authorities in the UAE and Saudi Arabia have implemented measures to streamline drug approval processes, making it easier for innovative therapies to enter the market. This regulatory support, combined with the region's growing healthcare infrastructure, positions the Middle East as an attractive destination for biopharma companies looking to expand their global footprint.
Furthermore, partnerships like the one between Burjeel Holdings and BridgeBio Pharma contribute to knowledge transfer and capacity building in the region. By collaborating with international biopharma companies, local entities gain access to cutting-edge research and technology, allowing them to enhance their own capabilities in drug discovery and development